Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs

Diabetes

Volumn 48, Issue 5, 1999, Pages 1045-1053

  Sandhu, Harmanjit ^a   Wiesenthal, Stephanie R ^a   MacDonald, Patrick E ^a   McCall, Richard H ^a   Tchipashvili, Vaja ^a   Rashid, Shirya ^a   Satkunarajah, Malathy ^a   Irwin, David M ^a   Shi, Z Qing ^a   Brubaker, Patricia L ^a   Wheeler, Michael B ^a   Vranic, Mladen ^a   Efendic, Suad ^b   Giacca, Adria ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLYCEROL; INSULIN; RECEPTOR; SOMATOSTATIN;

ADIPOSE TISSUE; ARTICLE; DOG; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GLUCOSE UTILIZATION; HORMONE ACTION; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; LIPOLYSIS; MALE; MUSCLE; NONHUMAN; PANCREAS RESECTION; PRIORITY JOURNAL;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOGS; FATTY ACIDS, NONESTERIFIED; FEMALE; GENE EXPRESSION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; GLYCEROL; INSULIN; KINETICS; MALE; PANCREATECTOMY; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RECEPTORS, GLUCAGON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOMATOSTATIN;

EID: 0032956247     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.5.1045     Document Type: Article

References (47)

1. Orskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35:701-711, 1992
2. Freyse EJ, Becher T, El-Hag O, Knospe S, Goke B, Fischer U: Blood glucose lowering and glucagonostatic effects of glucagon-like peptide 1 in insulin-deprived diabetic dogs. Diabetes 46:824-828, 1997
3. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S: Glucagonostatic and insulinotropic action of glucagon-like peptide-1 (7-36) amide. Diabetes 38:902-905, 1989
4. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
5. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I: Potent glycogenic effect of GLP-1(7-36) amide in rat skeletal muscle. Diabetologia 37:1163-1166, 1994
6. Yang H, Egan JM, Wang Y, Taha C, Moyes CD, Roth J, Montrose MH, Montrose-Rafizadeh C: GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 275:C675-C683, 1998
7. Furnsinn C, Ebner K, Waldhausl W: Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38:864-867, 1995
8. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, Villanueva-Penacarrillo ML: Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349:313-316, 1994
9. Nakagawa Y, Kawai K, Suzuki H, Ohashi S, Yamashita K: Glucagon-like peptide-1 (7-36) amide and glycogen synthesis in the liver. Diabetologia 39:1241-1242, 1996
10. Oben J, Morgan L, Fletcher J, Marks V: Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide, glucagon-like polypeptide-1 (7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 130:267-272, 1991
11. Miki H, Namba M, Nishimuri T, Mineo I, Matsumura T, Miyagawa J, Nakajima H, Kuwajima M, Hanafusa T, Matsuzawa Y: Glucagon-like peptide-1(7-36) amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochem Biophys Acta 1312:132-136, 1996
12. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J: Glucagon-like peptide 1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinol 135:2070-2075, 1994
13. Ruiz-Grande C, Alarcon C, Merida E, Valverde I: Lypolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 13:13-16, 1992
14. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
15. D'Alessio DA, Prigeon RL, Ensinck JW: Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. Diabetes 44:1433-1437, 1995
16. D'Alessio D, Quddusi S, Laschansky E, Vogel R, Prigeon R: Glucagon-like peptide 1 decreases hepatic glucose production independent of insulin and glucagon (Abstract). Diabetes 46 (Suppl. 1):29A, 1997
17. Gutniak M, Orskov C, Holst J, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
18. Myers S, Williams V, Broderick C, Baker J, Workman R: GLP-1 does not affect insulin sensitivity in the normal dog (Abstract). Diabetes 45 (Suppl 2):233A, 1996
19. Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KGMM, Schmitz O: GLP-1 does not affect insulin sensitivity in healthy man. Diatetologia 39:1227-1232, 1996
20. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:413-478, 1997
21. Vranic M, Pek S, Kawamori B: Increased "glucagon immunoreactivity" in plasma of totally depancreatized dogs. Diabetes 23:905-912, 1974
22. Giacca A, Fisher S, Shi ZQ, Gupta R, Lickley L, Vranic M: Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. J Clin Invest 90:1769-1777, 1992
23. 14C glucose. Recent Prog Horm Res 19:445-488, 1963
24. Finegood DT, Bergman RN, Vranic M: Estimation of endogenous glucose production during hyperinsulinemic euglycemic glucose clamp: comparison of labelled and unlabelled glucose infusate. Diabetes 36:914-924, 1987
25. Finegood DT, Bergman RN, Vranic M: Modelling error and apparent isotope discrimination confound estimation of endogenous glucose production during euglycemic glucose clamps. Diabetes 37:1025-1034, 1988
26. Giacca A, McCall RH, Chan B, Shi ZQ: Increased dependence of glucose production on peripheral insulin in diabetic depancreatized dogs. Metabolism 48:1-9, 1999
27. Rocca A, Brubaker PL Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinol 140:1687-1694, 1999
28. Miles JR, Glassock J, Aikens J, Gerich J, Haymond M: A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 24:96-99, 1983
29. Lloyd B, Burrin J, Smythe P, Alberti KGMM: Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-OH-butyrate. Clin Chem 24:1724-1729, 1978
30. Sambrook J, Fritsch EH, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1989
31. Wheeler MB, Lu M, Dillon JS, Leng X, Chen C, Boyd AE III: Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinol 133:57-62, 1993
32. Bradley DC, Steil GM, Bergman RN: Quantification of measurement error with optimal segments: basis for adaptive time course smoothing. Am J Physiol 264:E902-E911, 1993
33. Sindelar DK, Chu CA, Rohlie M, Neal DW, Swift LL, Cherrington AD: The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog. Diabetes 46:187-196, 1997
34. Rebrin K, Steil GM, Mittelman SD, Bergman RN: Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest 98:741-749, 1996
35. Yip RGC, Boylan MO, Kieffer TJ, Wolfe MM: Functional GIF receptors are present on adipocytes. Endocrinol 139:4004-4007, 1998
36. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinol 137:2968-2978, 1996
37. Thorens B: Expression cloning of the pancreatic B cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 89: 641-8645, 1992
38. Wei Y, Moisov S: Distribution of GLP-1 and PACAP receptors inhuman tissues. Acta Physiol Scand 157:355-357, 1996
39. Barragan JM, Rodriguez RE, Blazquez E: Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266:E459-E466, 1994
40. McCall RH, Wiesenthal SR, Shi ZQ, Polonsky K, Giacca A: Insulin acutely suppresses glucose production by both peripheral and hepatic effects in normal dogs. Am J Physiol 274:E346-E356, 1998
41. Villanueva-Penacarrillo ML, Merida E, Delgado E, Molina LM, Arrieta F, Rovira A, Valverde I: Increased glucagon-like peptide 1 (7-36) amide binding in adipose tissue from non-insulin dependent and insulin-dependent diabetic patients. Diabetes Nutr Metab 7:143-148, 1994
42. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
43. Toft-Nielson M, Madsbad S, Holst JJ: The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556, 1996
44. Montrose-Rafizadeh C, Levine MA, Avdonin P, Schwindinger WF: Evidence for coupling of pancreatic GLP-1 receptor to different G-protein alpha subunits (Abstract). Diabetes 46 (Suppl. 1):188A, 1997
45. Srinivasan M, Begum N: Stimulation of protein phosphatase-1 activity by phorbol esters: evaluation of the regulatory role of protein kinase C in insulin action. J Biol Chem 269:16662-16667, 1994
46. Smal J, DeMeyts P: Sphingosine, an inhibitor of protein kinase C, suppresses the insulin-like effects of growth hormone in rat adipocytes. Proc Natl Acad Sci U S A 86:4705-1709, 1989
47. Kieffer TJ, Heller RS, Habener JF: Characterization of glucagon-like peptide-1 (GLP-1) binding sites on 3T3-L1 adipocytes (Abstract). 10th Int Congr Endocrinol 1:412A, 1996